UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Link zum Volltext

Verfügbarkeit prüfen

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.553-556.e3

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Link zum Volltext

Verfügbarkeit prüfen

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA dermatology (Chicago, Ill.), 2015-09, Vol.151 (9), p.961

2015

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S74

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Link zum Volltext

Verfügbarkeit prüfen

New and emerging therapies in psoriasis

Seminars in cutaneous medicine and surgery, 2014-03, Vol.33 (2 Suppl 2), p.S37-S41

2014

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.519-522

2020

Link zum Volltext

Verfügbarkeit prüfen

Data on the safety of psoriasis therapies

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S73-S75

Leonardi, Craig L

2014

Link zum Volltext

Verfügbarkeit prüfen

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Journal of the American Academy of Dermatology, 2009-07, Vol.61 (1), p.S1-S46

2009

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic development in psoriasis

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S69-S72

2014

Link zum Volltext

Verfügbarkeit prüfen

Subgroup analyses of etanercept in pediatric patients with psoriasis

Journal of the American Academy of Dermatology, 2010-08, Vol.63 (2), p.e38-e41

2010

Link zum Volltext

Verfügbarkeit prüfen

Efalizumab: an overview

Journal of the American Academy of Dermatology, 2003-08, Vol.49 (2), p.98-104

Leonardi, Craig L

2003

Link zum Volltext

Verfügbarkeit prüfen

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Journal of the American Academy of Dermatology, 2005-03, Vol.52 (3), p.425-433

2005

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Journal of drugs in dermatology, 2013-08, Vol.12 (8), p.888

2013

Link zum Volltext

Verfügbarkeit prüfen

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Journal of drugs in dermatology, 2016-05, Vol.15 (5), p.562

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial

Journal of the American Academy of Dermatology, 2006-04, Vol.54 (4), p.S154-S163

2006

Link zum Volltext

Verfügbarkeit prüfen

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

Diagnostic pathology, 2008-03, Vol.3 (1), p.13-13, Article 13

2008

Link zum Volltext

Verfügbarkeit prüfen

Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

Journal of the American Academy of Dermatology, 2006-03, Vol.54 (3), p.S92-S100

2006

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Aktive Filter

ThemaPsoriasis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Dermatology
(54)
Science & Technology
(52)
Humans
(51)
Life Sciences & Biomedicine
(50)
Biological And Medical Sciences
(31)
Medical Sciences
(31)
Psoriasis - Drug Therapy
(29)
Female
(25)
Male
(25)
Adult
(18)
Middle Aged
(18)
Psoriasis. Parapsoriasis. Lichen
(15)
Treatment Outcome
(15)
Polymerase Chain Reaction
(13)
Severity Of Illness Index
(12)
Aged
(11)
Antibodies, Monoclonal - Therapeutic Use
(9)
Infectious Diseases
(9)
Antibodies, Monoclonal - Adverse Effects
(8)
Double-Blind Method
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

New and emerging therapies in psoriasis

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Data on the safety of psoriasis therapies

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Therapeutic development in psoriasis

Subgroup analyses of etanercept in pediatric patients with psoriasis

Efalizumab: an overview

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

Guidelines of care for the management of psoriasis and psoriatic arthritis

Guidelines of care for the management of psoriasis and psoriatic arthritis

Aktive Filter

Suchergebnisse filtern